| ²é¿´: 615 | »Ø¸´: 1 | |||
18234074933гæ (³õÈëÎÄ̳)
|
[ÇóÖú]
Çó·ÒëÂÛÎÄÌâÄ¿ºÍÕªÒª
|
|
RTB Lectin: a novel receptor- independent delivery system for lysosomal enzyme replacement therapies Enzyme replacement therapies have revolutionized patient treatment for multiple rare lysosomal storage diseases but show limited efectiveness for addressing pathologies in ¡°hard-to-treat¡± organs and tissues including brain and bone. Here we investigate the plant lectin RTB as a novel carrier for human lysosomal enzymes. RTB enters mammalian cells by multiple mechanisms including both adsorptive-mediated and receptor-mediated endocytosis, and thus provides access to a broader array of organs and cells. Fusion proteins comprised of RTB and human ¦Á-L-iduronidase, the corrective enzyme for Mucopolysaccharidosis type I, were produced using a tobacco-based expression system. Fusion products retained both lectin selectivity and enzyme activity, were efciently endocytosed into human fbroblasts, and corrected the disease phenotype of mucopolysaccharidosis patient fbroblasts in vitro. RTB-mediated delivery was independent of high-mannose and mannose-6- phosphate receptors, which are exploited for delivery of currently approved lysosomal enzyme therapeutics. Thus, the RTB carrier may support distinct in vivo pharmacodynamics with potential to address hard-to-treat tissues. ·¢×ÔСľ³æAndroid¿Í»§¶Ë |
» ²ÂÄãϲ»¶
Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤´óѧ£¬³õÊԳɼ¨350Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
¸´ÊÔµ÷¼Á
ÒѾÓÐ4È˻ظ´
323·Ö£¨¼ÆËã»úÊÓ¾õºÍ´óÄ£ÐÍÏîÄ¿£©ÄÜÖ±½ÓÉÏÊÖ
ÒѾÓÐ3È˻ظ´
311·Ö 22408 Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
320·ÖÈ˹¤ÖÇÄܵ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸Ö£´ó0705Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
0703»¯Ñ§
ÒѾÓÐ10È˻ظ´
301Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
306·Ö²ÄÁÏÓ뻯¹¤Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
ÁøÒ¶µ¶
гæ (³õÈëÎÄ̳)
- ·ÒëEPI: 1
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 29.8
- Ìû×Ó: 11
- ÔÚÏß: 3.6Сʱ
- ³æºÅ: 4177589
- ×¢²á: 2015-10-27
- ÐÔ±ð: GG
- רҵ: ¼ÆËã»úÈí¼þ
|
RTBÄý¾ÛËØ£ºÒ»ÖÖÕë¶ÔÈÜøÌåÃ¸Ìæ´úÁÆ·¨µÄÐÂÐÍÊÜÌå¶ÀÁ¢´«ÊäÌå ·¢×ÔСľ³æAndroid¿Í»§¶Ë |
2Â¥2015-11-02 19:59:17














»Ø¸´´ËÂ¥